Ataxin-3, the disease protein in Machado-Joseph disease, is known to be proteolytically modified by various enzymes including two major families of proteases, caspases and calpains. This processing results in the generation of toxic fragments of the polyglutamine-expanded protein. Although various approaches were undertaken to identify cleavage sites within ataxin-3 and to evaluate the impact of fragments on the molecular pathogenesis of Machado-Joseph disease, calpain-mediated cleavage of the disease protein and the localization of cleavage sites remained unclear. Here, we report on the first precise localization of calpain cleavage sites in ataxin-3 and on the characterization of the resulting breakdown products. After confirming the occurrence of calpainderived fragmentation of ataxin-3 in patient-derived cell lines and post-mortem brain tissue, we combined in silico prediction tools, western blot analysis, mass spectrometry, and peptide overlay assays to identify calpain cleavage sites. We found that ataxin-3 is primarily cleaved at two sites, namely at amino acid positions D208 and S256 and mutating amino acids at both cleavage sites to tryptophan nearly abolished ataxin-3 fragmentation. Furthermore, analysis of calpain cleavage-derived fragments showed distinct aggregation propensities and toxicities of C-terminal polyglutamine-containing breakdown products. Our data elucidate the important role of ataxin-3 proteolysis in the pathogenesis of Machado-Joseph disease and further emphasize the relevance of targeting this disease pathway as a treatment strategy in neurodegenerative disorders. Keywords: ataxin-3; calpains; cleavage sites; Machado-Joseph disease; spinocerebellar ataxia type 3 Abbreviations: EGFP = enhanced green fluorescent protein; iPSC = induced pluripotent stem cell; MJD = Machado-Joseph disease; polyQ = polyglutamine; SCA = spinocerebellar ataxia
Introduction
Proteolytic cleavage of disease proteins has been proposed as a key event in the molecular pathogenesis of various neurodegenerative diseases like Alzheimer's disease (De Strooper, 2010 ) and Parkinson's disease (Xilouri et al., 2013) , or the group of polyglutamine (polyQ) disorders (Weber et al., 2014) . This post-translational processing constitutes the source for fragments of mutant proteins, which exhibit elevated cytotoxic characteristics and aggregation propensities, ultimately leading to cell death and neurodegeneration. The discovery of this mechanism led to the formulation of the so called 'toxic fragment hypothesis' (Wellington and Hayden, 1997) .
The presence of proteolytically derived breakdown products has been reported for all polyQ diseases, and was intensively investigated in Machado-Joseph disease (MJD; also known as spinocerebellar ataxia type 3, SCA3), spinocerebellar ataxia type 7 (SCA7), and Huntington's disease (DiFiglia et al., 1997; Wellington et al., 1998; Yvert et al., 2000; Goti et al., 2004) . Since then, research has focused on the identification of enzymes responsible for the fragmentation of the involved proteins, as they represent an auspicious target for pharmacological treatments of these incurable diseases (Tarlac and Storey, 2003) .
Ataxin-3 (ATXN3), the disease protein in MJD, was shown to be a substrate for mainly two families of proteases: caspases and calpains (Wellington et al., 1998; Berke et al., 2004; Haacke et al., 2007; Jung et al., 2009; Koch et al., 2011; Hü bener et al., 2013) . Caspases are cysteine proteases that usually cleave after a C-terminal aspartate residue and are known to be involved in apoptotic and inflammatory pathways, but also to play a crucial role in cell proliferation, differentiation, and migration (Li and Yuan, 2008; McIlwain et al., 2013) . Calpains, a class of Ca 2 + -dependent regulatory cysteine proteases, show a more complex selection for the cleavage site recognition motif and are specialized in modulating structure, localization, and activity of their substrates Smith and Schnellmann, 2012) .
Although both groups of enzymes are reportedly active in processing ataxin-3, most recent research has focused on calpains, as their intrinsic Ca 2 + -sensitivity directly links these proteases with the disrupted Ca 2 + homoeostasis observed in MJD and other neurodegenerative diseases (Chen et al., 2008; Bezprozvanny, 2009; Koch et al., 2011) . First in vivo studies demonstrated beneficial effects on neuropathology and behavioural phenotype of MJD animals, when inhibiting calpain activity pharmacologically or overexpressing the endogenous calpain inhibitor calpastatin (Simoes et al., 2012; Simõ es et al., 2014).
Several putative calpain cleavage sites within ataxin-3 were described and their localization narrowed down to positions around amino acids 60, 200, 260 (Haacke et al., 2007 ), 190 (Colomer Gould et al., 2007 , or 154 and 220 (Simoes et al., 2012) , respectively. Concordantly, C-terminal fragment constructs comprising amino acids, which encompass the polyQ tract, showed a notably enhanced cytotoxicity and aggregation propensity compared to full-length mutant ataxin-3 (Ikeda et al., 1996; Paulson et al., 1997; Haacke et al., 2006; Invernizzi et al., 2012) . However, the exact sites and the impact of the consequent fragments remain elusive.
Here, we report on the successful precise identification and characterization of calpain cleavage sites within the ataxin-3 protein. After confirming our previous results that ataxin-3 is cleaved both by calpain-1 and calpain-2 in vitro, and that calpain-derived cleavage fragments can be observed in animal models of MJD (Hü bener et al., 2013) , we now verified the existence of these specific breakdown products in patientderived cell lines and MJD post-mortem brain tissue. In addition, we engaged in the determination of cleavage sites using an elaborated combination of in silico prediction tools, western blot analysis, mass spectrometry, and peptide overlay assays. By this means, we detected four prominent calpain cleavage sites in the ataxin-3 protein, with two major sites at amino acids D208 and S256. Furthermore, we effectively abolished calpain cleavage of ataxin-3 by exchanging amino acids at identified sites by triple-tryptophan motifs and analysed the impact of ataxin-3 proteolysis by overexpressing cleavage site-corresponding fragment constructs. Our data pave the way for subsequent in vivo studies and help to better understand calpain-dependent proteolytic events in MJD as a target for pharmacological treatments.
Material and methods

Ethical statement on human research
Informed consent was acquired for all patients from whom skin biopsies were obtained. Skin biopsies and experiments on human material were approved by the ethics committee of the University of Tü bingen (NEUROMICS No. 598/ 2011BO1) . Tissue was obtained and used in accordance with the Declaration of Helsinki.
Prediction of calpain cleavage sites in silico
In silico prediction of the calpain cleavage sites in the ataxin-3 protein (isoform 2; UniProt identifier: P54252-2) was performed using the GPS-CCD (group-based prediction system-calpain cleavage detector) software (Liu et al., 2011) . Scores for every amino acid position were graphically visualized using GraphPad Prism 6.00 for Windows (GraphPad Software Inc.).
Expression constructs
The pDsRed2-ER vector was obtained from Clontech (Takara Bio). For generation of Strep/FLAG-tagged ataxin-3 constructs, ataxin-3 (cDNA for isoform 2; UniProt identifier: P54252-2) 15Q and 62Q was cloned into the pDEST-(N)SF TAP by Gateway Õ cloning as described previously (Gloeckner et al., 2007) . Calpain cleavage site mutated ataxin-3 constructs were cloned by inserting gBlocks Õ Gene Fragments (Integrated DNA Technologies), comprising the altered cleavage site sequence, into pEGFP-N1 ataxin-3 vectors (thankfully provided by Thorsten Schmidt) . For penta-alanine (5A) mutations at amino acid sites H187, D208 and S256, restriction enzymes SpeI and XmnI were used. For triple-tryptophan (3W) mutations at sites H187, D208 and S256, SpeI was replaced by SacII. Gene fragments featuring 5A and 3W mutations at amino acid site T277 were inserted using SacII and BbsI. For calpain cleavage-corresponding fragment constructs, DNA fragments were generated by amplifying respective sequences of the ataxin-3 isoform 2 cDNA by PCR. Primer pairs used for amplification added HindIII (5') and KpnI (3') restriction sites flanking the PCR products. Sequences were cloned into a pEGFP-N1 vector via aforementioned restrictions sites. Expanded CAG repeats (148 CAG) were integrated into the constructs employing enzymes XmnI and PpuMI. All restriction enzymes used for cloning were obtained from NEB. Correct cloning of the constructs was confirmed by Sanger sequencing and functional overexpression tested by transient transfection in HEK293T cells.
Cell culture and transfection
Cell culture experiments were performed with HEK293T cells (ATCC: CRL-11268), SV40-immortalized human fibroblasts, generated from skin biopsies of a patient with MJD (23 and 67 CAG repeats) and an age-and gendermatched control (14 and 21 CAG repeats) (Supplementary Table 1 ), human primary fibroblasts and human fibroblastderived induced pluripotent stem cells (iPSCs).
HEK293T cells and SV40-immortalized human fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) GlutaMAX TM supplemented with 10%
foetal calf serum (FCS), 1% non-essential amino acids (MEM NEAA) and 1% antibiotic-antimycotic (all Gibco Õ , Thermo Fisher Scientific) at 37 C in 5% CO 2 . Transfection of HEK293T cells was done using Attractene reagent (Qiagen) according to the manufacturer's protocol.
For overexpression of SF-tagged ataxin-3 and subsequent protein purification, HEK293T cells were cultured in 14 cm dishes in DMEM medium (PAA) supplemented with 10% FCS (PAA) and appropriate antibiotics. Cells were transfected at a confluence between 50-70% with 8 mg plasmid DNA/dish using polyethyleneimine (PEI) (Polysciences) solution as described previously (Ben-Zimra et al., 2002) . After transfection, cells were cultured for 48 h.
Reprogramming of fibroblasts to induced pluripotent stem cells
Skin biopsies were obtained from three patients with MJD and four healthy control subjects (Supplementary Table 1) . Each biopsy was dissected and left undistributed in fibroblast medium consisting of DMEM high glucose with 10% FCS for 10 days at 37 C and 5% CO 2 to allow fibroblasts to grow out from the biopsy. Expansion of skin fibroblast was achieved by medium change every 2-3 days. For reprogramming 10 5 fibroblasts were electroporated (Nucleofector 2D, Lonza) with a total of 1 mg per plasmid carrying the sequences for hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28 and cultured in fibroblast medium for 1 day (Okita et al., 2011) . After 2 days of cultivation in fibroblast medium containing 2 mg/l FGF-2 (Peprotech), cells were transferred to Essential 8 (E8) medium containing 100 mM NaB (Sigma-Aldrich). After $21-28 days, iPSC colonies were picked manually and further expanded on Matrigel Õ -coated 6-well dishes cultivated with E8 medium. After reaching confluency cells were split in a ratio of 1:6-1:12 with 0.02% EDTA in Dulbecco's phosphate-buffered saline (DPBS) and further expanded. At passage 7-10, iPSCs were harvested for analysis or frozen in E8 medium with 40% KOSR (Gibco Õ , Thermo Fisher Scientific), 10% DMSO (Sigma-Aldrich), and 1 mM Y-27632 (Abcam Biochemicals). Generated iPSCs were carefully characterized including exclusion of plasmid-integration, screening for genomic aberrations, resequencing of mutation site, confirmation of expression of pluripotency markers, and verifying the in vitro differentiation potential (for an example see Hauser et al., 2016) (data not shown).
Neuronal differentiation of induced pluripotent stem cells
Differentiation of iPSCs to cortical neurons was done as described previously (Shi et al., 2012) . Briefly, neural induction was achieved by dual SMAD inhibition (10 mM SB431542 and 500 nM LDN-193189; both SigmaAldrich) and cultivation in 3N medium. Medium was changed every day and cells collected at Day 10 by dissociation with Accutase Õ (Thermo Fisher Scientific) followed by replating in 3N medium supplemented with 20 ng/ml FGF2. At Day 12, FGF2 was withdrawn and cells were further cultivated in 3N medium with medium change every other day. Cell cultures were passage once more by dissociation with Accutase Õ and replated at a density of 
Lysate preparation and western blotting
Cell lysates were prepared as follows. Transfected and treated HEK293T cells were detached by rinsing with cold DPBS (Gibco Õ , Thermo Fisher Scientific). Treated MJD patient-and control-derived SV40-immortalized fibroblasts were collected by trypsinization followed by pelleting at 300g for 5 min and washing with cold DPBS. All cells were again pelleted at 300g for 5 min and lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate and 1% Triton TM X-100), containing cOmplete TM protease inhibitor cocktail (Roche) for 25 min on ice, while vortexing every 5 min. Samples were centrifuged at 13 200g for 15 min at 4 C. Afterwards, the supernatant was transferred into a precooled reaction tube, adding glycerol to final concentration of 10%. Lysates of human cerebellar tissue were obtained by homogenizing the sample in RIPA buffer containing cOmplete TM protease inhibitor cocktail using a ULTRA-TURRAX Õ disperser (VWR). Homogenates were incubated for 25 min on ice and centrifuged at 13 200g for 30 min at 4 C. The supernatant was transferred into a precooled reaction tube and mixed with glycerol to a final concentration of 10%. Protein concentrations of RIPA lysates were measured spectrophotometrically using Bradford reagent (Bio-Rad Laboratories).
Western blotting was performed according to standard procedures. Briefly, 30 mg of protein were mixed with 4 Â LDS sample buffer (1 M Tris Base pH 8.5, 2 mM EDTA, 8% LDS, 40% glycerol, 0.075% CBB G, 0.025% phenol red) and 100 mM DTT, and heat denatured for 10 min at 70 C. Subsequently, protein samples were separated electrophoretically using 10% Bis-Tris gels, 4-12% Bolt Õ Bis-Tris gradient gels or 7% NuPAGE Õ Tris-Acetate 
Cytoplasmic/nuclear fractionation
For separation of cytoplasmic and nuclear proteins, the REAP (Rapid, Efficient And Practical) fractionation method was used with minor modifications (Suzuki et al., 2010) . Briefly, transfected HEK293T cells were detached by rinsing with cold DPBS and pelleted at 300g. Pellets were resuspended in DPBS-N (DPBS, 0.1% NP-40, and cOmplete TM protease inhibitor). An aliquot was taken as total cell sample. The remainder was centrifuged for 10 s at 10 000g. The supernatant was transferred into a fresh tube and declared as the cytoplasmic fraction. The pellet was washed once with DPBS-N and centrifuged again for 10 s at 10 000g. The supernatant was discarded and the pellet, containing the nuclear fraction, was resuspended in LDS buffer with 100 mM DTT. Total cell sample and cytoplasmic fraction were mixed with LDS buffer with 100 mM DTT, ultrasonicated for 10 s and analysed by western blotting. Purity of obtained fractions was confirmed by western blotting using a-tubulin as a cytoplasmic marker and histone H3 as a nuclear marker (antibody mouse anti-histone H3; 1:2000; clone mAbcam 10799, Abcam).
Protein purification
Purification of Strep/FLAG (SF)-tagged ataxin-3 from HEK293T cells was performed as described previously (Gloeckner et al., 2009 (Gloeckner et al., , 2010 . Briefly, after removal of the medium cells were lysed in 1 ml lysis/washing buffer (50 mM Tris pH 7.4, 100 mM NaCl) supplemented with 0.55% NP-40 and cOmplete TM protease inhibitor cocktail, per 14 cm dish. Incubation with lysis buffer was then performed for 40 min at 4 C on a shaker. Cell debris and nuclei were removed by centrifugation of the lysates at 10 000g for 10 min. Cleared lysates were incubated with Strep-Tactin Õ Superflow Õ resin (IBA) for 1 h at 4 C. Beads were transferred to micro-spin columns (GE Healthcare) and washed five times with 500 ml washing buffer prior final elution using 400 ml elution buffer [washing buffer supplemented with 200 mM D-desthiobiotin (IBA)].
Calpain activation assay in vitro
In vitro calpain activation assays using purified recombinant proteins or cell extracts were performed as previously described (Hü bener et al., 2013) . Briefly, for calpain cleavage of recombinant ataxin-3, 5 mg of His 6 -ataxin-3 (R&D Systems) or purified SF-tagged ataxin-3 were diluted in 400 ml calpain reaction buffer (20 mM HEPES/KOH pH 7.6, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT). The positive control was incubated with recombinant calpain-1 or calpain-2 (Merck Millipore), and 2 mM CaCl 2 for indicated molar ratios and times at room temperature. Calpain activity of all samples was quenched by adding 100 mM
and 20 mM EDTA. When needed, 100 mM of the pan-caspase inhibitor Q-VD-OPh (Merck Millipore) were added to block caspase activation.
For in vitro calpain activation using cell culture lysates, cell pellets were incubated in calpain lysis/reaction buffer (20 mM HEPES/KOH pH 7.6, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 0.1% Triton TM X-100) for 25 min on ice, while vortexing every 5 min. Samples were centrifuged at 13 200 g for 15 min at 4 C. Afterwards, the supernatant was transferred into a precooled reaction tube and protein concentrations were measured spectrophotometrically using Bradford reagent. Lysates were diluted in calpain reaction buffer to obtain a final protein concentration of 1.5 mg/ml. For negative control, lysates were preincubated with 100 mM of the calpain inhibitor CI III for 10 min on ice. To activate endogenous calpains, 2 mM CaCl 2 were added and incubated at 37 C under constant agitation for indicated times. For quenching the reaction and further western blot analysis, as described above, samples were mixed with 4 Â LDS sample buffer and 100 mM DTT, and heat denatured for 10 min at 70 C.
Quantitative mass spectrometric analysis
Strep/FLAG (SF)-tagged ataxin-3 with 15Q or 62Q repeats was either expressed in HEK293T cells cultured in heavy (lysine-8; aginine-10) or light (lysine-0, arginine-0) SILAC medium and purified via the Strep-tag II as described previously (Gloeckner et al., 2009) . For calpain cleavage induction, 5 mg of purified heavy-labelled ataxin-3 was incubated with recombinant calpain-1 or calpain-2 as described above. Calpain-treated and control samples were mixed in a 1:1 ratio and samples were precipitated by chloroform/methanol and redissolved in 50 mM ammonium bicarbonate, containing 0.2% RapiGest TM (Waters), reduced with DTT and alkylated with iodoacetamide. In addition, a reverse experiment was performed by switching the labels between the conditions. Proteolysis was carried out by adding GluC or AspN (both NEB) at 37 C overnight. The RapiGest TM surfactant was hydrolysed and removed and samples were further purified via C18-StageTips (Thermo Fisher Scientific) following standard protocols. Samples were subsequently analysed by LC-MSMS using a nano-flow HPLC system (Dionex Ultimate 3000 RSLC, Thermo Fisher Scientific) coupled to a QExactive TM Plus tandem mass spectrometer (Thermo Fisher Scientific). To identify peptides specific to the calpain cleavage, quantification of the resulting MS-data was performed. The raw data were directly analysed by the MaxQuant software ver. 1.5.2.8 (Cox et al., 2009 ) allowing protein identification and quantification with the following Andromeda search-engine parameters: database: custom ataxin-3 database (66 entries), containing typical protein IDs previously identified in ataxin-3 affinity purifications, carbamidomethyl as fixed modification as well as N-terminal protein acetylation as variable modification with the heavy/light (H/L) isotope pairs lysine-0/arinine-0 and lysine-8/arginine-10 for quantification. As enzyme either GluC or AspN and semi-specific cleavage mode were chosen. The initial mass accuracy (MS) for mass recalibration was set to 20 ppm. For MSMS spectra, the mass accuracy was set to 0.1 Da. The false discovery rate (FDR) threshold was set to 0.01. Razor-peptides and peptides with N-terminal acetylation or methionine oxidation were included into protein quantification. Downstream analysis and graphical representation was carried out using Perseus v. 1.5.2.6. Peptides corresponding to ataxin-3 appearing at least in one forward (H: calpain treatment; L: control condition) and one reverse experiment (label switch) were filtered out. Each condition ('Ratio H/L normalized' values of MaxQuant output) was then renormalized by division by their medians. A combined analysis was performed for the calpain-1/2 isoforms and the different ataxin-3 polyQ repeats, 15Q and 62Q. Peptides with a normalized H/L ratio greater than 2 in the forward experiment and a normalized H/L ratio below 0.5 in the reverse condition were considered as robust hits.
Peptide array synthesis, calpain overlay and immunodetection
Putative calpain cleavage sites in ataxin-3 and alanine or tryptophan mutations thereof were synthesized as 20-mer peptides on cellulose membranes using a MultiPep automated peptide synthesizer (INTAVIS Bioanalytical Instruments AG) (Frank and Overwin, 1996) .
Calpain overlay experiments were performed as previously described (Wanichawan et al., 2014) . Briefly, the peptide array membranes were first activated in methanol for 10 s followed by three washes of 10 min in TBS-T. Thereafter, the membranes were blocked in 1% casein overnight at 4 C before overlaying with 1 mg/ml of calpain-1 (human erythrocytes, 208713, Calbiochem) or calpain-2 (porcine kidney, 208715, Calbiochem) in calpain buffer (20 mM HEPES pH 7.5, 10 mM EGTA, 0.1% Triton TM X-100, 20 mM CaCl 2 ) overnight at 4 C with gentle agitation. Membranes incubated without any calpain protein were used as negative control. The membranes were then washed five times for 5 min in TBS-T and incubated with primary antibody rabbit anti-calpain (1:1000; sc-30064, Santa Cruz) for 1 h at room temperature, washed five times for 5 min in TBS-T, and incubated with the HRPconjugated secondary antibody donkey anti-rabbit IgG (NA934V, GE Healthcare). Chemiluminescence signals were developed by ECL Prime western blotting detection reagent (RPN 2232, GE Healthcare) and detected using ImageQuant TM LAS-4000 imager (Fujifilm). Densitometric analysis of detected signals was performed using the ImageJ software (Schneider et al., 2012) .
Filter retardation assay
For the detection of SDS-insoluble ataxin-3 species, transfected HEK293T cells were homogenized in DPBS-T (DPBS with 1% Triton TM X-100 and cOmplete TM protease inhibitor cocktail) by ultrasonication for 10 s. Protein concentrations of the homogenates were determined spectrophotometrically using Bradford reagent and 12.5 mg of total protein were diluted in DPBS containing 2% SDS and 50 mM DTT. Samples were heat denatured for 5 min at 95 C and cooled down to room temperature to prevent precipitation of SDS. A nitrocellulose membrane (Amersham TM Protran TM 0.45 mm, GE Healthcare) was equilibrated in 0.1% SDS in DPBS and samples were filtered through this membrane using a Minifold Õ II Slot Blot System (Schleicher & Schuell). The membrane was rinsed once with TBS and blocked with 5% SlimFast in TBS for 1 h at room temperature. Membranes were detected using the standard immunodetection protocol, see 'Western blotting' section. Retained SDS-insoluble ataxin-3 was detected using the antibodies mouse rabbit anti-ataxin-3 (1:500; SA3637, Schmidt et al., 1998) or rabbit anti-ubiquitin (1:500; Z0458, Dako, Agilent Technologies).
Denaturing detergent agarose gel electrophoresis
Electrophoretical separation and analysis of high molecular species of ataxin-3 was performed according to the protocol for semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) (Halfmann and Lindquist, 2008) , with the modifications stated below. For sample preparation, 25 mg of cell homogenate were mixed with 4 Â loading buffer (2 Â TAE buffer, 40% glycerol, 8% SDS, 0.05% bromophenol blue) with 50 mM DTT, and heat denatured for 5 min at 95 C. Samples were electrophoretically separated on a 0.75% TAE agarose gel with 0.1% SDS using a PerfectBlue TM Gel System Mini S (Peqlab) at 3 V per cm gel length. Afterwards, proteins were transferred on Amersham TM Protran TM Premium 0.2 mm nitrocellulose membranes (GE Healthcare) using Bicine/Bis-Tris transfer buffer with 10% methanol, and a TE22 Transfer Tank (Hoefer) at 80 V for 2 h. Membranes were detected using the standard immunodetection protocol. For detecting high molecular species of ataxin-3, antibodies rabbit anti-ataxin-3 (1:500; SA3637, Schmidt et al., 1998) or rabbit anti-ubiquitin (1:500; Z0458, Dako, Agilent Technologies) were applied. Huntingtin was detected as a loading control using a rabbit anti-huntingtin antibody (1:1000; clone D7F7, #5656, Cell Signaling).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.00 for Windows (GraphPad Software Inc.). Statistical significance of datasets obtained by western blot, DDAGE and FACS was determined using one-way-ANOVA and Tukey post-test. For calpain overlay experiments, statistical differences were tested using one-way ANOVA with Bonferroni post-test. P-values 5 0.05 were considered as statistically significant, with 
Results
In silico prediction of calpain cleavage sites in the ataxin-3 protein
The precise mechanism of cleavage site recognition by calpains remains elusive, making predictions of putative cleavage sites a challenging task. Many structural features of the substrate protein seem to contribute to its specificity including determinants like primary/secondary protein structures or PEST regions (sequences rich in proline, glutamic acid, serine, and threonine) (Tompa et al., 2004; duVerle et al., 2011; Liu et al., 2011) .
To perform an in silico prediction approach for calpain cleavage sites within the ataxin-3 protein, we used the GPS-CCD tool (Group-based Prediction System -Calpain Cleavage Detector; freely available at http://ccd.biocuckoo. org/), which is based on a dataset of 368 experimentally verified sites in 130 substrate proteins (Liu et al., 2011) . Using the canonical protein sequence of the ataxin-3 isoform 2 (UniProt identifier: P54252-2), we could identify 24 major sites with a cleavage likelihood score above the maximum default cut-off value of 0.654. High scores for the polyQ repeat were considered as an artefact of the prediction. To narrow down the choice of promising sites, we selected those with protruding cleavage likelihood scores in comparison to the surrounding region (Fig. 1A) . A detailed list with the main sites is given in Supplementary  Table 2 .
Calpain-1 and calpain-2 cleave wildtype and mutant ataxin-3 at similar sites in vitro
To reconfirm ataxin-3 as a substrate for calpains in vitro, we performed calpain activation assays by incubating recombinant His 6 -ataxin-3 22Q with increasing amounts of recombinant calpain-1 and calpain-2. Using a set of antibodies with epitopes along the ataxin-3 sequence (Fig. 1B) , we investigated resulting fragments via western blotting and observed comparable cleavage patterns for both calpains with corresponding N-terminal and C-terminal ataxin-3 fragments (Fig. 1C and D) . Furthermore, when repeating the experiment with Strep/FLAG (SF)-tagged ataxin-3 15Q and 62Q in a time-dependent manner, no major differences between wild-type and polyQ-expanded ataxin-3 fragments became apparent ( Supplementary Fig.  2 ). However, on closer examination of resulting cleavage patterns, we identified a consistent group of presumably Nterminal ataxin-3 breakdown products and labelled them with letters 'a' to 'e' according to their expected cleavage site position from the N-to the C-terminus (Fig. 1C and D,  Supplementary Fig. 2 ). Overall, these data suggest that wild-type and polyQ-expanded ataxin-3 are cleaved mainly at similar cleavage sites by both calpain-1 and calpain-2.
Calpain-dependent ataxin-3 cleavage is present in patient-derived cells and post-mortem brain tissue
After modelling calpain-cleavage in vitro, we sought to investigate the presence of calpain-dependent ataxin-3 cleavage in patient-derived cell lines and post-mortem brain tissues. For this purpose, we treated SV40-immortalized fibroblasts, which were derived from a patient with MJD and an age-and gender-matched control, with the calpain inhibitor CI III for 2 h. Western blotting revealed that pharmacologic suppression of calpain activity, as verified by decreased levels of calpain-cleaved a-spectrin (black arrowhead; Fig. 2A ), a lower ratio of active to inactive calpain-1 and elevated levels of calpastatin ( Fig. 2A) , led to the reduction of a predominant ataxin-3 fragment in both cell lines ('c'; Fig. 2A ), pointing to its calpain cleavage-dependent origin. When triggering calpain activity in lysates of immortalized fibroblasts by adding CaCl 2 (Fig.  2B) or treating the cells with the ionophore ionomycin (Fig.  2C) , we could concordantly increase the levels of fragment 'c'. Furthermore, we detected two further calpain-derived fragments ('b' and 'd'; Fig. 2C ) of minor intensity using an antibody raised against the N-terminus of ataxin-3.
In addition to the investigations on immortalized fibroblasts, we analysed ataxin-3 cleavage in primary fibroblasts, iPSCs and iPS-derived differentiated cortical neurons (iCNs) of further MJD patients and healthy controls. By this, we reconfirmed the appearance of the predominant, presumably calpain-derived fragment 'c' (Fig. 3A) . According to expectations, treating iPSCs but also iCNs with ionomycin led to further fragmentation of ataxin-3 and elevated levels of fragment 'c' (Fig. 3B-D) and to a weaker extent fragment 'd' (Fig. 3D) , which was prevented by preincubation with CI III. Ultimately, western blotting of post-mortem cerebellar tissue of a patient with MJD and a respective control unveiled the appearance of calpain-dependent ataxin-3 cleavage in vivo (Fig. 3E and Supplementary Fig. 3 ).
In summary, calpains cleave ataxin-3 in patient and control-derived cell lines, and in post-mortem brain tissue, emphasizing the physiological relevance of calpainmediated proteolysis of ataxin-3. (C and D) Purified ataxin-3 (Atx3) 22Q is cleaved by recombinant calpain-1 (rCAPN1) and calpain-2 (rCAPN2) in vitro. Characteristic fragment patterns can be detected using four different ataxin-3-specific antibodies. iv CCA = in vitro calpain cleavage assay; S/E ratio = substrate/enzyme ratio; fl = full-length. Ataxin-3 fragments are labelled with letters 'a' to 'e' according to their expected cleavage site position from the N-to the C-terminus.
Deletion constructs unveil calpain cleavage sites in ataxin-3
As we reconfirmed calpain-dependent ataxin-3 cleavage in vitro and additionally observed fragmentation of the disease protein in patient-derived cell lines and post-mortem tissue, we raised the question at which particular sites ataxin-3 is proteolytically processed by calpains.
To exclude that the observed ataxin-3 fragments are resulting from caspase-dependent cleavage as an indirect effect of calpain activation, we initially performed a control experiment with lysates of EGFP-ataxin-3 15Q and 148Q expressing HEK293T cells. Activation of calpains by addition of CaCl 2 induced ataxin-3 cleavage, which could be prevented by the calpain inhibitor, ALLN. However, administration of the pan-caspase inhibitor Q-VD-OPh could not prevent cleavage of ataxin-3, which demonstrated the calpain-dependent origin of arising fragments ( Supplementary Fig. 4) . In a first attempt to screen for cleavage regions, we used EGFP-tagged deletion constructs of ataxin-3 lacking C-terminal portions of the protein, which were overexpressed in HEK293T cells. After activating calpains via ionomycin administration, we analysed the cleavage patterns of the deletion constructs by western blotting (Fig. 4A) . By comparing fragmentation between the deletion constructs and correlating disappearance of specific fragments with lacking C-terminal portions of ataxin-3, we were able to narrow down cleavage sites to regions between amino acids 321-366 (fragment 'a'), 244-259 (fragment 'c'), 198-243 (fragment 'd'), and right before position 198 (fragment 'e') ( Fig. 4B) . However, the region that comprises the fragment 'b' cleavage site could not be clearly defined via this approach.
Mass spectrometry reveals calpain cleavage sites within ataxin-3
After roughly estimating calpain cleavage sites using ataxin-3 deletion constructs, we performed a quantitative mass spectrometric approach to precisely map these sites in ataxin-3. Strep/FLAG (SF)-tagged ataxin-3 15Q or 62Q was expressed in HEK293T cells grown either in heavy or light SILAC medium and purified afterwards. Heavylabelled ataxin-3 was incubated with calpain-1 or calpain-2 and mixed with an untreated light-labelled ataxin-3 control in a 1:1 ratio. To rule out labelling artefacts, a reverse experiment was performed by switching the labels between the conditions. A scheme of the mass spectrometric mapping approach and the representative control western blots of calpain-cleaved heavy-labelled ataxin-3 are shown in Fig.  5A -C. The mixture was then subsequently subjected to proteolytic cleavage with either GluC, cleaving C-terminal from glutamate, or AspN, cleaving N-terminally from aspartate. For the final analysis, only peptides that were identified in a forward as well as in a reverse experiment were considered. The method allowed the identification of calpain cleavage sites via the peptides significantly enriched in the calpain-treated condition. Peptides enriched by at least 2-fold in the forward experiment and decreased by at least 2-fold in the reverse experiment were considered as robust hits. In addition, an outlier analysis, the Significance A test (Cox and Mann, 2008) was performed for forward and reverse experiments separately. These peptides showed semi-canonical cleavage patterns for GluC and AspN supporting the assumption that the observed non-canonical cleavage sites correspond to calpain cleavage sites. By this approach the sites H187 and D208 (GluC condition) as well as S256 and G259 (AspN condition) could be identified. H187 and D208 showed Significance A values of P 5 0.001 in the forward as well as reverse experiment. G259 showed a Significance A of P 5 0.005 in both experiments. For S256 the Significance A test returned values for the forward and reverse experiment of P = 0.061 and P = 0.0001, respectively. Scatter plots showing a combined analysis for the GluC and AspN secondary proteolytic cleavage for the different polyQ repeat lengths and calpain-1/2 isoforms are presented in Fig. 5D and E.
Triple tryptophan substitutions as a strategy to reduce cleavage likelihood Standard approaches to prevent calpain cleavage of substrates comprise alanine substitutions of up to 10 amino acids or deletion mutagenesis of whole cleavage sites (Gafni et al., 2004; Wanichawan et al., 2014) . To optimize this approach, we computed effects on the cleavage likelihood when replacing one to five amino acids of a predicted site by proteinogenic amino acids. Exchanging a single amino acid did not lead to marked alterations of the cleavage likelihood (Supplementary Fig. 5A ). However, replacing three or five amino acids led to a strong reduction of the cleavage likelihood, only when introducing cysteine (triple: À51%, quintuple: À81%), tryptophan (triple: À77%, quintuple: À85%), or tyrosine residues (triple: À58%, quintuple: À62%), as exemplarily predicted for site D208 ( Supplementary Fig. 5B and C) . Interestingly, classical alanine substitutions barely reduced likelihood or rather caused an increase (triple: + 19% quintuple: À1%). As cysteines and tyrosines are known to be eminent targets of post-translational modifications, we selected the lesser effected tryptophan as a triplet for mutagenesis of putative cleavage sites together with quintuple alanine substitutions as a classical approach (Fig. 6A) .
Calpain overlay of 20-mer ataxin-3 peptide arrays shows reduced binding after triple tryptophan substitution
To verify cleavage sites and to prove that a triple tryptophan substitution is indeed reducing cleavage likelihood or substrate recognition as seen in silico, we performed calpain overlay assays using an array of immobilized 20-mer peptides, which represent sequences around predicted cleavage sites in ataxin-3. Peptides were synthesized as unchanged sequences, or featuring triple tryptophan or quintuple alanine substitutions at predicted sites. Peptides were spotted and immobilized on a membrane and overlaid by calpain-1 or calpain-2. Calpain-specific immunodetection visualized binding of calpains to the respective motifs and verified sequences around sites H187, D208 and S256 (Fig. 6B-D) , which we previously mapped by mass spectrometry, as calpain recognition motifs.
Furthermore, peptides representing putative sites T277 and, to a weaker extent, E349 exhibited calpain binding, indicating further cleavage positions ( Fig. 6E and Supplementary Fig.  6A ). On the other hand, peptides comprising sites L62, S309, and G327, did not show any immunoreactivity for calpains ( Supplementary Fig. 6B-D) . When introducing a tryptophan triplet at putative cleavage sites, we observed marked reductions of the calpain immunoreactivity for all investigated peptides, except for site S256 and calpain-1 (Fig. 6D) . However, quintuple alanine substitutions showed only a clear reduction for sites H187 and T277, with an even stronger decrease for the latter site when compared to a tryptophan triplet ( Fig. 6B and E) . Notably, introduction of five alanines increased the binding of calpain-2 at site D208 and calpain-1 at site S256 ( Fig. 6C and D) .
Triple tryptophan mutagenesis of putative calpain cleavage sites reduced ataxin-3 fragmentation After observing decreased calpain binding to ataxin-3 peptides featuring tryptophan mutations at putative cleavage For mass spectrometry analysis, purified recombinant SF-tagged ataxin-3 15Q and 62Q were incubated with recombinant calpain-1 (rCAPN1) or calpain-2 (rCAPN2). To monitor the reaction, aliquots of the sample were analysed using SDS-PAGE. Total protein stain with SYPRO Ruby shows that ataxin-3 is cleaved by both calpains producing comparable patterns of polyQdependent and -independent fragments. N-terminal and C-terminal breakdown products were detected via immunodetection using antibodies against the FLAG-tag and against ataxin-3 (SA3637). iv CCA = in vitro calpain cleavage assay; bdp = breakdown product. (D and E) Scatter plots for the combined quantitative mass spectrometry approach. Log 2 median ratios of the forward experiments were plotted over the log 2 median ratios of the reverse experiments (label switch). Calpain-1/2 treatment following either a GluC or AspN secondary proteolysis allowed the identification of the calpain cleavage sites H187, D208 and S256 and G259. A minimum ratio of 2 in the forward experiments and a minimum ratio of 0.5 in the reverse experiments have been set as significance level (red line).
sites, we sought to confirm these effects on the full ataxin-3 protein. As cell-based calpain cleavage induction primarily gave rise to fragments 'c' and 'd', we focused on sites which not only were identified by mass spectrometry and calpain overlay assays but also presumably represent the origin of the two aforementioned breakdown products. For this, we generated C-terminally EGFP-tagged ataxin-3 15Q and 148Q constructs featuring quintuple alanine or triple tryptophan substitutions on cleavage positions D208, S256 or both sites. Following overexpression of respective ataxin-3 variants in HEK293T cells, we subjected lysates to in vitro calpain activation assays and analysed resulting ataxin-3 fragmentation patterns using N-terminally binding and EGFP-specific antibodies on western blots. When comparing unmodified ataxin-3 with variants carrying quintuple alanine substitutions at positions D208 or S256, only a reduction of the N-terminal fragment corresponding to cleavage at amino acid S256 was observed (Fig. 7A and Figure 6 Overlay of 20-mer ataxin-3 peptide arrays with calpain-1 and calpain-2 shows reduced calpain binding after triple tryptophan substitution. (A) In silico prediction of calpain cleavage sites in ataxin-3 (UniProt identifier: P54252-2) using the GPS-CCD tool and effects of replacing amino acids surrounding predicted cleavage sites by five alanines or three tryptophans on calpain cleavage likelihood. The red dotted line indicates maximum default cut-off value of 0.654. (B-F) Calpain binding to putative cleavage sites in ataxin-3 was analysed by overlaying cleavage site-containing 20-mer ataxin-3 peptides with calpain-1 (rCAPN1) and calpain-2 (rCAPN2). Cleavage positions are located after the redlabelled amino acid. Replacement of amino acids at the putative cleavage sites H187, D208 and S256 indicates the most efficient reduction of calpain binding when introducing three tryptophans. However, calpain binding at site T277 (D) is most reduced by introducing five alanines. For each site, detected peptide arrays of two representative experiments are shown. Bars represent means AE SEM, relative to wild-type sequence and n = 6. * P 5 0.05; ** P 5 0.01; *** P 5 0.001 (one-way ANOVA with Bonferroni post-test).
B). However, mutagenesis using tryptophan triplets at positions D208 or S256 nearly abolished respective N-terminal cleavage products ( Fig. 7A and B) . According to expectations, triple tryptophan exchanges also led to a concurrent reduction of corresponding C-terminal ataxin-3 15Q and 148Q fragments ( Fig. 7C and D) . Interestingly, mutating both sites led to an enhanced formation of an additional fragment, likely to correspond to cleavage site T277 ('b'; Fig. 7C and D). It should be mentioned that the cleavage of ataxin-3 is very weak at baseline, making it difficult to identify alterations of the fragmentation pattern in an uninduced state. Cell-based activation of calpains by administering ionomycin, h- Bars represent means AE SEM, relative to wild-type and n = 3. * P 5 0.05; ** P 5 0.01, *** P 5 0.001 (one-way ANOVA with Tukey post-test).
(C and D) Triple tryptophan (3W) cleavage site mutations at positions D208 and S256, or at both sites in ataxin-3 15Q and 148Q show reduced levels of corresponding C-terminal (antibody: GFP) and N-terminal (antibody: N-term-I) fragments. Actin served as loading control. C-terminal ataxin-3 fragments corresponding to N-terminal fragments 'a' to 'd' are marked with an apostrophe ('a 0 ' to 'd 0 '). (E) HEK293T cells transfected with EGFP-ataxin-3 15Q and 148Q with or without 3W mutations at positions D208 and S256 were subjected to a cell-based calpain cleavage assay (cb CCA). Detection with antibody N-term-II shows a strongly reduced occurrence of fragments 'c' and 'd' upon ionomycin (IM)-facilitated Ca 2 + influx for ataxin-3 208/256 3W when compared to the unmutated variants. Activation of the calpain system was validated by detecting calpain-1 activation and a-spectrin cleavage. Tubulin served as loading control. bdp = breakdown product; SE = short exposure; LE = long exposure.
owever, revealed a strongly reduced formation of fragments 'c' and 'd' in ataxin-3 carrying tryptophan triplets at positions D208 and S256, when compared to unmutated ataxin-3 using western blotting (Fig. 7E) . In retrospect to our previous fragment labelling, we were able to assign the detected fragment 'c' to cleavage site S256 and fragment 'd' to cleavage site D208. An overview of all predicted and identified calpain cleavage sites in our study can be found in Fig. 8A . In summary, cleavage site mutagenesis using tryptophan triplets turned out as an effective approach to decrease calpain cleavage of ataxin-3.
Fragment constructs as a tool for modelling aggregation and toxicity of calpain-cleaved ataxin-3
As calpain cleavage of overexpressed ataxin-3 was low at baseline, and in addition, stimuli that activate calpains are leading to detrimental side effects for treated cells, we generated EGFP-labelled ataxin-3 fragment constructs representing breakdown products at identified calpain cleavage sites D208 and S256 (Fig. 8B ) and overexpressed them in HEK293T cells (Fig. 8C and F) .
Overexpression of C-terminal polyQ-expanded fragment constructs corresponding to cleavage at both sites, D208 and S256, led to a strong accumulation of high molecular and SDS-insoluble ataxin-3 species when compared to fulllength ataxin-3 148Q. Furthermore, these ataxin-3 aggregates showed a marked ubiquitination (Fig. 8D) . Confocal microscopy of cells expressing the C-terminal fragment constructs together with the endoplasmic reticulum (ER)-labelling protein DsRed2-ER revealed a mainly cytoplasmic to perinuclear formation of occasionally massive ataxin-3 aggregates ( Fig. 8E and Supplementary Fig. 7 ). On the other hand, respective N-terminal ataxin-3 fragment constructs did not aggregate (Fig. 8G) . To analyse the impact of Cterminal polyQ-expanded fragment constructs on viability, we performed FACS analyses of transfected (EGFP-positive) HEK293T cells. Our investigations showed distinctly elevated cell death, when overexpressing both polyQ-expanded fragment constructs in comparison to full-length ataxin-3 148Q (Fig. 8H) .
Fragmentation of ataxin-3 by calpains or caspases was hypothesized to lead to a separation of the intrinsic N-terminally located nuclear export signals and the C-terminally located nuclear localisation signals, which might cause a relocation of C-terminal polyQ fragments to the nucleus. To investigate this, we overexpressed full-length and fragment constructs of ataxin-3 in HEK293T cells and analysed localization using cytoplasmic/nuclear fractionation and confocal imaging (Supplementary Fig. 8 ). Subcellular fractionation pointed to a mainly cytoplasmic localization of both full-length ataxin-3 and its fragment constructs, regardless of their N-or C-terminal origin ( Supplementary  Fig. 8A and B) . C-terminal fragments did not specifically demonstrate a shift toward the nucleus. Furthermore, microscopy showed a mainly diffuse distribution of all ataxin-3 variants within the cell, confirming the absence of a nuclear shift of C-terminal fragment constructs ( Supplementary Fig. 8C and D) .
Taken together, C-terminal polyQ-expanded fragment constructs of ataxin-3, representing calpain cleavage at positions D208 or S256, feature a higher aggregation propensity and elevated cytotoxicity when compared to the polyQexpanded full-length protein. However, these fragments do not show alterations in the cellular localization when compared to intact ataxin-3.
Discussion
The discovery of proteolytic ataxin-3 cleavage as a relevant contributor to the molecular pathogenesis of MJD opened up further possibilities to develop more directed therapeutics against this highly disabling disorder. To date, mainly caspases and calpains were associated with ataxin-3 fragmentation, and genetic or pharmacologic inhibition of these enzymes, or modification of recognition sites within their substrates seems to be a promising approach. In particular, inhibition of calpains in vivo was investigated intensively, showing that overexpression of calpastatin using adeno-associated viral vectors in a lentiviral mouse model of MJD did not only reduce ataxin-3 proteolysis but also decreased ataxin-3 aggregation and mediated neuroprotection (Simoes et al., 2012) . In line with these observations, the oral administration of the calpain inhibitor BDA-410 exerted comparable beneficial effects on fragmentation, aggregation and neurodegeneration (Simõ es et al., 2014) . On the other hand, non-specific or excessive inhibition of enzymes might lead to adverse effects due to disturbance of their physiological functions (Donkor, 2011; Li and Sheng, 2012; Kudelova et al., 2015; Baudry and Bi, 2016) .
In our study, we focused on the identification of calpain cleavage sites in ataxin-3 and on their genetic modification to prevent proteolytic processing at determined positions. Previous investigations on caspase-dependent fragmentation of ataxin-3 could already identify major caspase cleavage sites within this disease protein and mutagenesis of specific aspartate residues partially blocked ataxin-3 fragmentation (Berke et al., 2004) . These findings were translated into a Drosophila model of MJD, which exhibited a slowed down progression of neurodegeneration when expressing caspase cleavage-resistant, polyQ-expanded ataxin-3 (Jung et al., 2009) . Although localization of putative calpain cleavage sites has been narrowed down by western blotting or Edman N-terminal sequencing, exact sites remained unknown or lacked further confirmation by site-directed mutagenesis (Haacke et al., 2007; Simoes et al., 2012) .
Here, in our combinatorial approach, we were not only able to precisely localize calpain cleavage sites within ataxin-3, but also confirmed elected sites by mutating surrounding amino acids to render them less calpain cleavage- 256 and 257Cter ). C-terminal fragments were generated in two different polyQ-variants (wild-type 15Q and expanded 148Q). (C) Overexpression of calpain cleavage-corresponding C-terminal fragment constructs in HEK293T was analysed via western blotting. Insoluble forms of ataxin-3 in the stacking gel (SG) were detected for ataxinprone. In our in vitro and cell-based assays, we first reconfirmed wild-type and polyQ-expanded ataxin-3 as substrates for both calpain-1 and calpain-2. We did not detect differences between specificities and cleavage patterns regardless of expected polyQ-dependent size shifts. These observations add to results from studies using only recombinant calpain-2 (Haacke et al., 2007) . Furthermore, the lack of differences in cleavage efficiency between calpain-1 and calpain-2 stands in contrast with our previous study, where we detected stronger ataxin-3 cleavage by calpain-2 (Hü bener et al., 2013). Although previous attempts failed to identify proteolytic fragments in human MJD brain tissue or to associate them with specific proteases (Berke et al., 2004; Goti et al., 2004) , we unequivocally observed calpain-dependent ataxin-3 fragmentation in patient-and control-derived fibroblasts, iPSC lines and post-mortem brain tissue at baseline. In this respect, a previous study reported on calpain-dependent ataxin-3 cleavage and aggregation in patient-specific iPSC-derived neurons after inducing Ca 2 + influx via NMDA or glutamate administration (Koch et al., 2011) . More recent investigations using similar approaches, however, could not reproduce the glutamate-induced ataxin-3 aggregation (Hansen et al., 2016) .
To analyse observed ataxin-3 fragments and to identify calpain-cleavage sites within the protein sequence, we first predicted cleavage sites in ataxin-3 in silico using the GPS-CCD tool. After comparing predicted sites with results obtained by quantitative mass spectrometry and calpain overlay assays, we were able to identify four major cleavage sites at positions H187, D208, S256 and T277, matching with previous results obtained by Edman sequencing (Haacke et al., 2007) . However, cleavage sites at amino acids Q154 or G220 as proposed in a more recent publication (Simoes et al., 2012) were neither observed in our experiments nor reached high scores in our in silico prediction. By correlating expected fragment sizes with the prior observed cleavage patterns, sites D208 and S256 emerged as primary calpain targets. Interestingly, these two cleavage sites co-localize with known phospho-sites in ataxin-3, namely sites T207 and S256.
The not yet intensively investigated site T207 was predicted to be phosphorylated by CK2 Mueller et al., 2009) . Site S256 was shown to be targeted by GSK 3b and the dephosphomimetic variant S256A of polyQ-expanded ataxin-3 was shown to be highly aggregation-prone when compared to unchanged or phospho-mimetic S256D ataxin-3 (Fei et al., 2007) . Together with our findings, these observations underline the huge relevance of both investigated sites for the protein homoeostasis of ataxin-3 and reveal the modulation of phosphorylation as a putative approach to manipulate ataxin-3 cleavage. In line with this, phosphorylation of huntingtin, the disease protein in Huntington's disease, was shown to reduce its cleavage by caspases (Luo et al., 2005) .
To prevent ataxin-3 fragmentation by cleavage site-directed mutagenesis, we sought to modify common approaches based on polyalanine substitutions or cleavage site deletions (Gafni et al., 2004; Wanichawan et al., 2014) . Although mutagenesis of single amino acids following the 'P2-P1 rule' of substrate recognition has been shown to be sufficient in preventing calpain cleavage (Hirao and Takahashi, 1984; Sasaki et al., 1984; Stabach et al., 1997; Kaczmarek et al., 2012) , further studies could not confirm the preference of calpains for any particular residues or demonstrated that alteration of the sequence at only one position was not sufficient to block calpain-dependent cleavage (Sakai et al., 1987; Banik et al., 1994; Garg et al., 2011) . Due to these inconsistencies, we decided to use in silico prediction to test the effects of a single to multiple amino acid substitutions by all proteinogenic amino acids. By this approach, we identified a triple tryptophan motif as the most potent mutation to decrease cleavage likelihood. Calpain overlay assays of cleavagesite containing peptides carrying this triplet confirmed a significant reduction of calpain binding, which was more efficient than a penta-alanine substitution. Finally, this effect was corroborated by generating wild-type and polyQ-expanded ataxin-3 variants featuring penta-alanine and triple tryptophan mutations at cleavage sites D208 and S256. Thus, triple tryptophan substitutions constitute a potent way to prevent calpain cleavage at mutated recognition motifs, which can be applied to further calpain substrates.
To characterize the impact of cleavage-site corresponding fragments further, we generated respective EGFP-tagged ataxin-3 constructs comprising N-and C-terminal portions of the wild-type and polyQ-expanded protein. It should be noted that our C-terminal fragment construct 257Cter corresponds directly to a prior generated construct, whose sequence was based on results of unspecified limited proteolysis experiments with recombinant ataxin-3 (Haacke et al., 2006) . Only overexpression of C-terminal polyQ-expanded ataxin-3 led to a massive accumulation of ubiquitin-positive aggregates, which markedly exceeded aggregation of full-length ataxin-3 and increased cell death. This corresponds to cell and animal models of MJD, which show strong ataxin-3 accumulations, apoptosis and a more rapid manifestation of MJD-reminiscent phenotypes when compared to the expression of full-length mutant ataxin-3 (Ikeda et al., 1996; Paulson et al., 1997; Breuer et al., 2010) . The excessive ubiquitination of C-terminal fragment-derived aggregates, but not of aggregates composed of full-length polyQ-expanded ataxin-3, might be due to the elevated misfolding of truncated ataxin-3 species, which has been suggested earlier as a trigger for ubiquitination (Jana and Nukina, 2004) . Confocal microscopy of aggregates formed by our C-terminal fragment constructs exhibited a mainly cytoplasmic localization. Interestingly, a recent histological study on the aggregation pathology in the brainstem of SCA2 and MJD patients revealed the severity of cytoplasmic aggregates as the best predictor of neurodegeneration in both polyQ disorders, while an inverse correlation of neurodegeneration and nuclear aggregates was seen in MJD brain tissue (Seidel et al., 2016) . In addition, a further study that investigated aggregate toxicity of artificial b-sheet proteins, as well as fragments of polyQ-expanded huntingtin and TAR DNA binding protein-43 (TDP-43), discovered that cytoplasmic but not nuclear aggregation interfered with nucleocytoplasmic protein and RNA transport maybe contributing to the cellular pathology in proteinopathies (Woerner et al., 2016) . These findings suggest a rather protective role of aggregates localized in the cell nucleus. On the other hand, N-terminal fragment constructs did not show any SDS-insoluble or high molecular aggregation when overexpressed in cell culture, consistent with earlier in vitro experiments (Perez et al., 1998) , but out of line with our observations in an N-terminal fragment mouse model of MJD (Hü bener et al., 2011) . As fragmentation of ataxin-3 was connected to a separation of N-terminally located nuclear export signals (NES) and C-terminally located nuclear localization signals (NLS) (Antony et al., 2009) , we analysed the subcellular localization of ataxin-3. Our Cterminal fragment constructs 209Cter and 257Cter, which both contain NLS 273 and lack NES 77 and NES 141, did not exhibit a trend towards nuclear localization. These observations accord with previous investigations that showed that the endogenous NLS signal is not active and C-terminal ataxin-3 fragments without the NES might shuttle in and out of the nucleus (Breuer et al., 2010) . The nuclear accumulation of mutant ataxin-3, however, might be triggered by alternative NLS-independent processes.
In summary, we report on the identification of calpain cleavage sites within the ataxin-3 protein and on the successful cleavage prevention by substituting recognition motifs by tryptophan triplets. Furthermore, we could characterize calpain cleavage-derived fragments of ataxin-3. A still pending but not less important further step in analysing ataxin-3 cleavage and arising fragments will be the characterization of our generated cleavage site-mutant constructs in vivo. Only a physiological expression of the modified ataxin-3 variants in the correct organic context and a time-dependent manner can give us the chance to assess the impact of proteolytic cleavage on the molecular pathogenesis MJD. This approach was exemplified by previous studies, which were investigating caspase-dependent cleavage of ataxin-3 in Drosophila or polyQ-expanded huntingtin in mice (Graham et al., 2006; Jung et al., 2009 ). In addition, further investigations of C-or even N-terminal ataxin-3 fragments should be undertaken, as, for instance, polyQ-independent fragments of huntingtin showed deleterious effects on autophagy or vesicle transport (Martin et al., 2014; El-Daher et al., 2015) .
On a final note, our precise identification of calpain cleavage sites enables the development of an alternative possibility to prevent ataxin-3 fragmentation by skipping exons that contain the respective calpain recognition motif. This concept has already been tested for Huntington's disease by using antisense oligonucleotides that induce skipping of exon 12 in huntingtin pre-mRNA, and thereby abolish the formation of a toxic N-terminal huntingtin fragment (Evers et al., 2014) . On the other hand, focusing on the correction or removal of the expanded CAG repeat might still represent a more specific approach Evers et al., 2013) .
Overall, our data emphasize the biological relevance of calpain-mediated ataxin-3 cleavage and underline this proteolytic pathway as a potential therapeutic target for treating MJD.
